{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["23(10)"],"submitter":["Mannarino L"],"pubmed_abstract":["Pleural mesothelioma (PM) is an aggressive tumor with few therapeutic options. Although patients with epithelioid PM (ePM) survive longer than non-epithelioid PM (non-ePM), heterogeneity of tumor response in ePM is observed. The role of the tumor immune microenvironment (TIME) in the development and progression of PM is currently considered a promising biomarker. A few studies have used high-throughput technologies correlated with TIME evaluation and morphologic and clinical data. This study aimed to identify different morphological, immunohistochemical, and transcriptional profiles that could potentially predict the outcome. A retrospective multicenter cohort of 129 chemonaive PM patients was recruited. Tissue slides were reviewed by dedicated pathologists for histotype classification and"],"journal":["International journal of molecular sciences"],"pagination":["5786"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9144737"],"repository":["biostudies-literature"],"pubmed_title":["Epithelioid Pleural Mesothelioma Is Characterized by Tertiary Lymphoid Structures in Long Survivors: Results from the MATCH Study."],"pmcid":["PMC9144737"],"pubmed_authors":["Moracci L","Vedovelli L","Inglesi A","Pezzuto F","Ceresoli GL","Bosetti C","Libener R","Allavena P","De Simone I","Zucali PA","Amodeo R","Penpa S","Marchini S","Olteanu GE","Callari M","De Angelis A","Calabrese F","Paracchini L","Delfanti S","Muzio A","Mannarino L","Lupi M","D'Incalci M","Grosso F"],"additional_accession":[]},"is_claimable":false,"name":"Epithelioid Pleural Mesothelioma Is Characterized by Tertiary Lymphoid Structures in Long Survivors: Results from the MATCH Study.","description":"Pleural mesothelioma (PM) is an aggressive tumor with few therapeutic options. Although patients with epithelioid PM (ePM) survive longer than non-epithelioid PM (non-ePM), heterogeneity of tumor response in ePM is observed. The role of the tumor immune microenvironment (TIME) in the development and progression of PM is currently considered a promising biomarker. A few studies have used high-throughput technologies correlated with TIME evaluation and morphologic and clinical data. This study aimed to identify different morphological, immunohistochemical, and transcriptional profiles that could potentially predict the outcome. A retrospective multicenter cohort of 129 chemonaive PM patients was recruited. Tissue slides were reviewed by dedicated pathologists for histotype classification and","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 May","modification":"2025-04-05T11:59:05.177Z","creation":"2024-11-05T20:39:53.338Z"},"accession":"S-EPMC9144737","cross_references":{"pubmed":["35628597"],"doi":["10.3390/ijms23105786"]}}